Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

FISHER SCIENTIFIC BIOTECH LINE ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.3% 1.3%   Bankruptcy risk   3.9% 3.9% 3.6% 3.4% 0.6% 0.4% 6.3% 6.3%   Credit score (0-100)   52 52 52 52 98 99 37 37   Credit rating   BBB BBB BBB BBB AA AAA BBB BBB   Credit limit (kDKK)   0.0 0.0 0.0 0.1 764,973.7 1,229,310.7 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   0.0 0.0 0.0 0.0 9,314 23,426 0.0 0.0   EBITDA   5,659 6,912 8,536 6,592 7,242 12,433 0.0 0.0   EBIT   5,659 6,912 8,536 6,592 7,216 12,409 0.0 0.0   Pre-tax profit (PTP)   -138,822.0 -174,403.0 -154,992.0 -7,195.0 125,145.0 10,232.0 0.0 0.0   Net earnings   -138,822.0 -174,403.0 -154,992.0 -7,195.0 124,169.0 8,010.0 0.0 0.0   Pre-tax profit without non-rec. items   5,659 6,912 8,536 6,592 125,145 10,232 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 24.0 0.0 0.0 0.0   Shareholders equity total   1,528,329 3,595,644 7,512,037 7,504,844 7,841,182 12,312,831 12,312,329 12,312,329   Interest-bearing liabilities   0.0 0.0 0.0 0.0 49,605 63,492 0.0 0.0   Balance sheet total (assets)   8,255,879 8,245,587 7,937,634 8,019,000 7,911,820 12,389,676 12,312,329 12,312,329   Net Debt   0.0 0.0 0.0 0.0 49,536 63,492 -12,312,329 -12,312,329     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   0.0 0.0 0.0 0.0 9,314 23,426 0.0 0.0   Gross profit growth   -100.0% 0.0% 0.0% 0.0% 0.0% 151.5% -100.0% 0.0%   Employees   11 13 13 12 12 13 0 0   Employee growth %   -8.3% 18.2% 0.0% -7.7% 0.0% 8.3% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   8,255,879 8,245,587 7,937,634 8,019,000 7,911,820 12,389,676 12,312,329 12,312,329   Balance sheet change%   0.5% -0.1% -3.7% 1.0% -1.3% 56.6% -0.6% 0.0%   Added value   5,659.0 6,912.0 8,536.0 6,592.0 7,216.0 12,433.0 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -46 0 0 0 -2 -48 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   0.0% 0.0% 0.0% 0.0% 77.5% 53.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   0.1% 0.1% 0.1% 0.1% 1.6% 0.2% 0.0% 0.0%   ROI %   0.1% 0.1% 0.1% 0.1% 1.6% 0.2% 0.0% 0.0%   ROE %   -8.7% -6.8% -2.8% -0.1% 1.6% 0.1% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   100.0% 100.0% 100.0% 100.0% 99.1% 99.4% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   0.0% 0.0% 0.0% 0.0% 684.0% 510.7% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.6% 0.5% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 17.6% 10.1% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0   Current Ratio   0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0   Cash and cash equivalent   0.0 0.0 0.0 0.0 69.0 0.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   0.0 0.0 0.0 0.0 -34,710.0 -38,484.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   514 532 657 549 601 956 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   514 532 657 549 604 956 0 0   EBIT / employee   514 532 657 549 601 955 0 0   Net earnings / employee   -12,620 -13,416 -11,922 -600 10,347 616 0 0